Claims
- 1. A method for treating bladder or urinary tract cancer in a human or veterinary patient, said method comprising the step of administering to the patient a therapeutically effective amount of a compound having the formula:
- 2. A method according to claim 1, where R5 is an oxygen atom that is connect to the β-carbon atom of the olefinic double bond to form a compound having the formula:
- 3. A method according to claim 1, where R2 is prenyl or other alkenyl and R3 is OH, wherein R2 and R3 are combined to form a cyclic ring structure and a compound having the formula:
- 4. A method according to claim 1, wherein R4 is prenyl or other alkyl, R3 is OH and said R3 and R4 are combined to form a cyclic ring structure and a compound of the formula:
- 5. A method according to claim 1 wherein R4 is prenyl or other alkyl, R5 is OH and are combined to form a cyclic ring and a compound having the formula:
- 6. A method according to claim 1, where R2 is prenyl or other alkenyl, R3 is OH and R2 and R3 combine to form a cyclic ring and a compound of formula:
- 7. A method According to claim 1 wherein R4 is prenyl or other alkenyl, R3 is OH and wherein R3 and R4 are combined to form a cyclic ring structure and a compound having the formula:
- 8. A method according to claim 1, wherein the compound is 4′-hydroxy-4,2′,6′-trimethoxychalcone.
- 9. A method according to claim 1, wherein the compound is 2′-hydroxy-4,4′,6′-trimethoxychalcone (Flavokawain A).
- 10. A method according to claim 1, wherein the compound is 2′-4-dihydroxy-4′,6′-dimethoxychalcone (Flavokawain C).
- 11. A method according to claim 1, wherein the compound is 2′,4,6′-trihydroxy-4-methoxy-3′-prenylchalcone (Xanthogalenol).
- 12. A method according to claim 1, wherein the compound is 2′,6′,4-trimethoxy-4′-hydroxy-3′-prenylchalcone.
- 13. A method according to claim 2, wherein where the compound is luteolin.
- 14. A method according to claim 2, wherein the compound is apigenin.
- 15. A method according to claim 3, wherein the compound is 2′,6′-dimethoxy-4-hydroxy-3′,4′-dehydrocyclohexanochalcone.
- 16. A method according to claim 4, wherein the compound is 2′,6′dimethoxy-4-hydroxy-4′,5′-dehydrocyclohexanochalcone.
- 17. A method according to claim 5, wherein the compound is 2′,4-dimethoxy-4′-hydroxy-5′,6′-dehydrocyclohexanochalcone.
- 18. A method according to claim 6, wherein the compound is 5,4′-dihydroxy-6,7-dehydrocyclohexanoflavone.
- 19. A method according to claim 7, wherein the compound is 5-hydroxy-4′-hydroxy-7,8-dehydrocyclohexanoflavone 4′-glucoside.
- 20. A method according to claim 1 wherein the compound is administered orally.
- 21. A method according to claim 1, wherein the compound is administered intravesically.
RELATED APPLICATION
[0001] This patent application claims priority ro U.S. Provisional Patent Application No. 60/459,495 entitled Treatment of Bladder and Urinary Tract Cancers Using Chalcome and Flavone Derivatives, which was filed on Apr. 1, 2003, the entirety of which is expressly incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60459495 |
Apr 2003 |
US |